KDM1A and breast cancer: Approximately, 15% fewer LSD1-deficient MCF-7 (Figure 1D) and 30% fewer LSD1-defiecient MDA-MB-468 cells (Figure 1E) survived after doxorubicin treatment, compared to scrambled siRNA-transfected cells, providing additional evidence that LSD1 plays a role in the chemoresistance of breast cancer cells.